|
|
|
| home > white papers > Planning the Execution of a Viral Clearance Study - Eurofins BioPharma Product Testing |
|
|
 WHITE PAPERS |
|
Eurofins BioPharma Product Testing
|
|
Planning the Execution of a Viral Clearance Study
|
|
Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Merck Introduces New Integrated Plug & Play Upstream Development Service
• Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up
• Tailored upstream development from a single source reduces time to clinic by 20 percent
• Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment
More info >> |
|
 |
White Papers |
 |
|
The Role of the CRO in Effective Risk-Based Monitoring
Medpace
The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >> |
|
 |
Industry Events |
 |
12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
8-11 February 2021, Vienna, Austria
In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >> |
|
|
|
